Mergers & Acquisitions

• Represented multiple portfolio companies of Apollo Global Management in connection with various restructuring, divestitures, and add-on transactions as well as other corporate and regulatory advice, including:
  • Trace3;
  • Invited (f/k/a Club Corp), including in its sale of BigShots to TopGolf Callaway Brands (NYSE: MODG);
  • Accent;
  • Shutterfly;
  • West Corp; and
  • Graanul Invest.  
• Charlesbank Capital Partners in multiple platform and add-on acquisitions including:
  • ImageQuix Holdings, LLC, a portfolio company of ASG Group which is owned by Alpine Investors;
  • Solve Advisors, and the subsequent acquisition by Solve Advisors of Advantage Data Inc.; and
  • Healthcare Fraud Shield, a SaaS-based software developer.
• Device42, in its acquisition by a syndicate led by Charlesbank and Berenson, and their subsequent exit to Freshworks (NASDAQ: FRESH) for $230 million.
• Berenson Capital Partners in its leveraged buyout of Interactive Digital Solutions and MedSitter.
• The family office of a leading Wall Street figure in the acquisition of:  
  • A national youth sports platform;
  • A regional paving company based in the Midwest;
  • A financial services business; and
  • A controlling minority position in a regional fitness platform.
• Motus, Inc. in an innovative leveraged buyout by Thoma Bravo, which combined Motus with Runzheimer Inc. to establish the leading vehicle management and reimbursement platform.
• AT Cross Company, a portfolio company of Clarion Capital Partners, in its acquisition of Sheaffer, BIC’s fine writing instrument business.
• Berenson & Company as the lead financial advisor to Getty Images (NYSE: GETY) in its announced $3.7 billion merger with Shutterstock (NYSE: SSTK).
• XCM Solutions, a cloud-based workflow solutions provider for professional tax and accounting firms, in its $160 million sale to Wolters Kluwer Tax & Accounting North America.
• Laddawn, Inc., a leading manufacturer of plastic bags and films for packing applications with over $145 million in annual net sales, to Berry Global Group, Inc. (NYSE: BERY).
• Kimberly-Clark Corporation in selling its transdermal, micro-needle drug delivery division (Sofusa) to Sorrento Therapeutics for a total of $310 million (including contingent consideration).
• C&S Wholesale Grocers’ purchase of the assets of Associated Wholesalers.
• Legacy.com, a Pamplona Capital-backed technology company, in multiple bolt-on acquisitions.
• GCM Grosvenor as a co-investor in several significant leveraged buyouts.
• Princeton Lightwave, a developer of LiDAR technology, in its sale to Argo AI, an investment vehicle of Ford Motor Company.
• Third Wave Recovery Systems (TWRX) in its acquisition of SRX, a leader in pharmaceutical rebate management services for the skilled nursing and long-term care industry.
• John Hancock Financial Network’s purchase of the assets of Transamerica Financial Advisors.
• JN Phillips Auto Glass in a leveraged buyout by CenterOak Partners LLC and subsequent combination with Techna Glass, Inc. to form TruRoad Holdings, Inc., the second largest autoglass repair company in the US.
• A founder-run insurance data analytics firm in its acquisition by a Stone Point Capital-backed platform company.
• The office of a leading Wall Street figure in multiple investments in:  
  • Multiple SPAC PIPE financings; and
  • A Major League Baseball team syndicate.
• The family office of a leading Wall Street figure in multiple investments in:
  • A medical device marketing business;
  • A craft liquor producer;
  • A technology-backed restaurant platform; and
  • A fast casual concept restaurant platform.
• KeraNetics, a Winston-Salem-based regenerative medicine business, in its merger with Microchips Biotech.
• Unizin in the spinout of its Internet 2 assets.
• Third Wave Recovery Systems in a growth equity investment from WindRose Health Investors, LLC.
• Synnovation Therapeutics in the sale of its PI3K program to Novartis for $2 billion upfront, with potential milestone payments of up to an additional $1 billion.
• Aurora Towers, a CVC DIF portfolio company, in its acquisition of American Tower Corporation's Canadian Wireless Tower Portfolio. 

Venture & Public Financings

• Bollé Brands, an Alvarez & Marsal Capital portfolio company, on the sale of its SPY+ and Serengeti eyewear brands to Safilo Group.
• Innovius Capital Management in connection with its role as lead investor in the $46 million Series B financing of xCures, an Oakland-based digital health company developing AI-driven solutions for medical record acquisition and analysis.
• NewVale Capital in its co-investment alongside JLL Partners in Commissioning Agents Inc. 
• ArriVent Biopharma, a clinical-stage company focused on innovative biopharmaceutical therapeutics in its:  
  • Formation and seed funding;
  • $150 million Series A financing;
  • $155 million Series B financing; and
  • IPO on Nasdaq raising gross proceeds of approximately $175 million.
• ProKidney LP, a clinical-stage cellular therapeutics company focused on chronic kidney disease, in its combination with Social Capital Suvretta Holdings Corp. III, a special purpose acquisition company (SPAC), resulting in approximately $597 million in gross cash proceeds and its subsequent listing on the Nasdaq (PROK).
• Viela Bio, a clinical-stage drug development company focused on early-stage inflammation and autoimmunity biologics, in its  
  • Spin-out from AstraZeneca’s MedImmune division;
  • $250 million Series A financing (the largest ever venture financing in Maryland);
  • Crossover financing round;
  • $172.6 million IPO; and
  • Sale to Horizon Therapeutics for $3 billion.
• Third Wave Recovery Systems in a growth equity investment from WindRose Health Investors, LLC.
• PleoPharma, an early-stage drug development company focused on addiction treatment, in a preferred financing from multiple investors.
• Synnovation Therapeutics, an early-stage drug development company, in a preferred financing.
• NexImmune, Inc., a Maryland-based immunotherapy company, in its:
  • Multiple private financing transactions; and
  • February 2021 IPO, which at the time was reported as the first upsized IPO at the top of its price range without a crossover.
• A small molecule drug development company in its $100 million Series A financing.
• The family office of a leading figure in the biotech industry in over a dozen minority investments in various early-stage biotechnology issuers.
• A medical device company in its $250 million Series D private placement.